Items Tagged ‘oncotype’

August 5th, 2015

Oncotype DX Increases Use of Active Surveillance in Prostate Cancer Patients

By

Genomic Health, Inc. announced that Urology Practice published results from the second clinical utility study of the Oncotype DX® prostate cancer test, showing that incorporation of the test’s Genomic Prostate Score (GPS) in treatment planning resulted in greater recommendations and acceptance of active surveillance as initial management of prostate cancer in low and low-intermediate risk […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, News, oncotype, Prostate Cancer, surveillance


December 10th, 2014

Oncotype DX® Predicts Outcomes in Prostate Cancer Patients, Significantly Changes Treatment Recommendations

By

CancerConnect News: Genomic Health, Inc. today announced results from two studies of the Oncotype DX® prostate cancer test demonstrating its value in low- and intermediate-risk prostate cancer to enable physicians and patients to avoid over- and under-treatment of the disease.  Both studies were presented, December 3, at the Society of Urologic Oncology (SUO) Annual Meeting, in […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, News, oncotype, Prostate Cancer, risk, treatment


October 1st, 2014

Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients

By

REDWOOD CITY, Calif., Sept. 29, 2014 – Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences’ (USU) Center for Prostate Disease Research (CPDR) supported by a multi-disciplinary team […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, genomics, News, oncotype, Prostate Cancer


September 22nd, 2014

Oncotype DX Colon Cancer Test May Reduce Medical Costs Associated with Stage II Disease While Increasing Patient Well-being

By

REDWOOD CITY, Calif., Sept. 12, 2014 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced that PharmacoEconomics published positive results from a health economic analysis suggesting that use of the Oncotype® DX colon cancer test may result in a significant reduction in direct medical costs and improve patient quality of life by helping them avoid side effects of unnecessary treatment. “By […]

View full entry

Tags: Adjuvant (I-III, A-C) Colon Cancer, Colon Cancer, early stage colon cancer, genomics, News, oncotype, stage 2 colon cancer


August 11th, 2014

Large Independent Validation Study Validates Oncotype DX Prostate Cancer Test

By

Genomic Health, Inc. announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer.  This study validated the Oncotype DX prostate cancer […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, News, oncotype, oncotype dx, Prostate Cancer, risk recurrence


June 9th, 2014

Data Demonstrates Benefit of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers

By

REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX® test and a new 16-gene panel to predict disease aggressiveness and clinical outcomes in prostate and renal cancers, respectively. These results, presented at the American Society of Clinical Oncology® (ASCO®) Annual […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, General Renal Cancer, genomic testing, kidney cancer, News, oncotype, Prostate Cancer, Renal Cancer